Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19762| Title: | Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. | Austin Authors: | Miller, Aaron E;Xu, Xianhao;Macdonell, Richard A L ;Vucic, Steve;Truffinet, Philippe;Benamor, Myriam;Thangavelu, Karthinathan;Freedman, Mark S | Affiliation: | Multiple Sclerosis Research Unit, Department of Neurology, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States Department of Neurology, Beijing Hospital, Beijing, China Department of Neurology, Austin Health, Heidelberg, Victoria, Australia Faculty of Medicine, University of Sydney, Sydney, Australia R&D, Sanofi, Chilly-Mazarin, France Global Pharmacovigilance & Epidemiology, Sanofi, Chilly-Mazarin, France Biostatistics, Sanofi, Cambridge, MA, United States |
Issue Date: | Jan-2019 | Date: | 2018-10-20 | Publication information: | Journal of Clinical Neuroscience 2019; 59: 229-231 | Abstract: | In the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were comparable between the Asian and overall populations, as were the rates for adverse events and serious adverse events, with no new or unexpected safety findings. These observations provide further evidence to support the clinical benefits and safety profile of teriflunomide in a broad range of patients with RMS. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/19762 | DOI: | 10.1016/j.jocn.2018.09.012 | Journal: | Journal of Clinical Neuroscience | PubMed URL: | 30348586 | Type: | Journal Article | Subjects: | Clinical trial Disease-modifying therapy Multiple sclerosis Phase 3 Subgroup analysis Teriflunomide |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.